Citadel, D.E. Shaw In Conv. Bond Settlement With Indian Pharmaceutical

Mar 11 2010 | 2:08pm ET

A pair of U.S. alternative investments giants has settled a legal battle with an Indian pharmaceutical company over its default on convertible bonds.

Venus Remedies said it has struck a deal with Citadel Investment Group and D.E. Shaw Group. The two firms had sued the company last year after Venus failed to redeem some US$12 million in foreign currency convertible bonds last summer. The pharma blamed the global economic crisis for its decision not to redeem the bonds.

Under the settlement—reached under pressure from the Indian courts—Citadel and D.E. Shaw have agreed to withdraw their winding-up petition, a Venus official told the Press Trust of India. The company will pay the two firms US$7 million within the next 18 months, with the other US$5 million coming over the next five years.

Citadel and D.E. Shaw will also get to keep their investments in Venus.


In Depth

An Interview With Harvest Volatility Management's Rick Selvala

Mar 23 2017 | 5:39pm ET

Several years of extremely low interest rates have pushed some investors into equities...

Lifestyle

'Tis the Season: Wall Street Holiday Parties Back In Fashion

Dec 22 2016 | 9:23pm ET

Spending on Wall Street holiday parties has largely returned to pre-2008 levels...

Guest Contributor

SEI: Private Debt Coming Into Its Own

Mar 8 2017 | 9:24pm ET

The explosive growth of private debt over the past few years has caused the lines...

 

From the current issue of